Mavatar Secures SEK 40 Million in Partial Funding Round, Advancing its Leadership in AI-Driven Precision Medicine

Mavatar, a Swedish leader in AI-driven precision medicine, today announced the successful completion of a SEK 40 million partial funding round. This strategic investment will accelerate the development of Mavatar's innovative platforms, Mavatar-Insight™ and Mavatar-Precision™, while expanding its operations and global reach.

Mavatar combines over 20 years of research in bioinformatics and artificial intelligence to transform drug discovery and personalized treatment. The Mavatar-Insight™ platform accelerates drug development by analyzing complex genomic data to identify new therapeutic targets and optimize clinical trials. The Mavatar-Precision™ platform creates patient-specific digital replicas—“medical avatars”—that simulate biological processes, enabling highly personalized treatments and improving patient outcomes, particularly in oncology and inflammatory bowel disease (IBD).

"We are thrilled to have secured this funding, which will enable us to scale rapidly and continue advancing our AI platforms," said Johan Juhlin, CEO of Mavatar. 

"This investment brings us closer to revolutionizing global healthcare with personalized medicine."

The funds will be used to expand operations, advance the Mavatar Insight and Precision ™ platforms, and prepare for a full commercial launch in 2026. Mavatar is also actively seeking additional strategic partners to support its ongoing growth.

Mavatar is a global specialist in AI-driven precision medicine solutions for all diseases. Built on over 20 years of scientific research, Mavatar’s proprietary DINA (Deep Integrated Network Analysis) framework powers two flagship platforms: Mavatar Discovery for accelerating disease and drug research, and Mavatar Precision for delivering personalized treatment recommendations in clinical care. By creating digital twins of both patients and diseases, Mavatar enables data-driven decisions that improve treatment outcomes, optimize clinical trials, and reduce healthcare waste. Headquartered [insert location], Mavatar is driving the future of truly personalized, scalable healthcare across all disease areas. We envision a future where everyone receives personalized, predictive and effective care—powered by Mavatar.

The Company has partnerships with leading pharmaceutical companies, universities, and hospital systems. These collaborations focus on biobank studies and clinical trials, enabling research scientists to select the best drug candidates, suggest new uses for existing drugs, uncover new therapeutic targets, refine mechanisms of action, and match patients to innovative treatment options through point-of-care decision tools.

Connect with us on LinkedIn.